Coronary Disease, Drug Eluting Stent, Dual Antiplatelet Therapy, Percutaneous Coronary Intervention
Conditions
Brief summary
This study is to assess the clinical non-inferiority of 1 month (short-term) vs 6 months (long-term) of dual anti-platelet therapy in patients undergoing percutaneous intervention implanted sirolimus -eluting stent with abluminal grooves containing a biodegradable polymer in High Bleeding Risk patients with coronary artery disease.
Detailed description
This is a prospective, double -blind,multi-center,randomized controlled trial. Approximately 1,720 subjects in high bleeding risk with coronary artery disease will be enrolled in no more than 40 research centers in China. All participants met the inclusion criteria will be 1:1 randomized to 1 month or 6months of DAPT after implanting Firehawk™ coronary stent. Clinical follow-up will be carried out at 30 days, 6 months, 12 months, 2 years after index procedure.The primary study endpoint is Net Adverse Clinical and Cerebral Events (NACCE), a composite of all-cause death, myocardial infarction (MI), cerebral vascular accident (CVA) and major bleeding (\[BARC\] definition) at 12 months. Subjects that complete of 12 months follow-up will be regarded as having completed the primary endpoint. The secondary study endpoints contain cost-effectiveness at 12 months, ARC defined stent thrombosis (ST) ; NACCE ;major adverse cardiovascular events (MACE),major adverse cardiovascular and cerebral events (MACCE),target lesion revascularization (TLR),target vessel failure(TVF) , major bleeding at 30 days,6,12 and 24 months of follow-up.
Interventions
DRUG1 month DAPT
Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 1 month, after which patients will be given ASA and placebo in next 5 months and then continue on monotherapy with ASA only, unless contraindications for ASA emerge.
DRUG6 months DAPT
Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 6 months, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
Sponsors
Shanghai MicroPort Medical (Group) Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Intervention model description
Parallel Assignment
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
General Inclusion Criteria: * Age ≥ 18 years; * Subjects (or legal guardians) understand the testing requirements and procedures, and provide written informed consent; * Subjects could undergo percutaneous coronary intervention (PCI); * Subjects have symptomatic coronary artery disease or have confirmed asymptomatic ischemia; * Subjects are eligible candidates for coronary artery bypass graft surgery (CABG); * Left ventricular ejection fraction (LVEF) within 60 days ≥ 30%; * Subjects were willing to accept the trial plan calls for all subsequent evaluations; * Subjects can endure 6 months dual anti-platelet therapy, and met one or more criteria as the following: 1.Age ≥ 75years; 2.Subjects with hemoglobin\<10g/dL, or subjects received transfusion therapy 4 weeks ago; 3.Subjects with renal insufficiency (eGFR \< 60 ml / min); 4. Subjects with HAS-BLED score ≥3.0; 5.Femal patients with acute cononary syndrome; 6.BMI \< 18.5 Kg/M2; 7.Subjects with congestive heart failure and with LVEF30%-50%; 8.Subjects had a history of hospitalization due to bleeding; 9.Subjects with thrombocytopenia (platelet \< 100,000 / mm3); 10.Subjects had a histroy of intracranial hemorrhage; 11.Subjects had a histroy of intracranial ischemia stroke in 6 months; 12.Subjects plan to receive non-steroidal anti-inflammatory or steroid treatment for more than 30 days after the baseline PCI; 14.Subjects were expected to receive additional treatment after PCI and cannot undergo long-term DAPT therapy; 15.Subjects had a history of stomach ulcers or active ulcers. Angiographic Inclusion Criteria * Target lesions must be new and have a visually estimated reference diameter ≥2.25 mm and ≤4.0 mm in autologous coronary artery; * Target lesions must be moderate-severe calcification; * No limitations in target lesion length and number, and the number of implanted stents is less than 4; * ALL target lesion must be able to successfully expand and implant Firehawk™ stent. Clinical
Exclusion criteria
* Subjects recently suffer from MI (within 4 week) and ECG changes/clinical symptoms consistent with AMI, or accompanied with increased cardiac biomarkers (CK-MB, CK, TNT or TNI) and at least one of the following : 1. CK-MB\> 3ULN, regardless of the value of total CK; 2. If CK-MB or CK was not detected, but cTN\> 1ULN, and at least one of the following: 1. Ischemic symptoms and ECG changes of new ischemia; 2. Development of pathologic Q waves in the ECG; 3. Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality. * Subject had Re-MI before randomized; * Subject with hemodynamic instability (Killip class IV); * Subjects were detected ventricular aneurysm greater than 3.0\*2.0cm or intraventricular thrombosis by cardiac ultrasonography in 30 days; * Subjects with Life-threatening arrhythmias; * Subjects were expected to receive oral anticoagulation therapy after the baseline PCI; * Subjects cannot endure dual anti-platelet therapy for 1 month; * Subjects with mechanical complications after myocardial infarction; * Subjects had an organ transplant or are waiting for an organ transplant; * Subjects are receiving chemotherapy or will receive a chemotherapy within 30 days after PCI; * Subjects with abnormal counts of white blood cell (WBC); * Subjects with verified or suspected acute liver disease, including lab results of acute liver disease; * Subjects had permanent neurological diseases in the past 6 months; * Subjects had any PCI (such as balloon angioplasty, stent, cutting balloon) treatment in target vessels within 12 months prior to baseline; * Non-target vessel had been implanted non-research stent 5 months ago before the baselin PCI. * Subjects plan to undergo PCI or CABG within 1 year after the baseline PCI; * Subjects have any coronary endovascular brachytherapy treatment previously; * Subjects associated with drugs allergy (such as sirolimus, or structure-related compounds fluorinated polymers, thiophenepyridine or aspirin); * Subjects are suffering from other serious illness (such as cancer, congestive heart failure), which may cause drop in life expectancy to less than 12 months; * Subjects are currently abusing drugs (such as alcohol, cocaine, heroin, etc); * Subject plan to undergo any operations that may lead to confuse with the programme; * Subjects were participating in another study of drug or medical device which did not meet its primary endpoint; * Subjects plan to pregnant within 12 months after baseline; * Subjects are pregnant or breastfeeding women. Angiographic
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Net Adverse Clinical and Cerebral Events (NACCE) | At 12 months after index procedure | A composite of all-cause death, MI, cerebral vascular accident (CVA) and major bleeding at 18 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Target Vessel Revascularization (TVR) | In hospital and at 30 days,6, 12 and 24 months after index procedure | — |
| Target lesion Revascularization (TLR) | In hospital and at 30 days,6, 12 and 24 months after index procedure | — |
| Target Vessel Failure (TVF) | In hospital and at 30 days,6, 12 and 24 months after index procedure | — |
| Target Lesion Failure (TLF) | In hospital and at 30 days,6, 12 and 24 months after index procedure | — |
| Stent Thrombosis (per ARC definition) | In hospital and at 30 days,6, 12 and 24 months after index procedure | the definite and probable stent thrombosis |
| Major Adverse Cardiac and Cerebral Events(MACCE) | In hospital and at 30 days,6, 12 and 24 months after index procedure | — |
| Myocardial Infarction (MI,including Q-wave MI and non Q-wave MI) | In hospital and at 30 days,6, 12 and 24 months after index procedure | — |
| Death (All cause, Cardiac, Non-cardiac) | In hospital and at 30 days,6, 12 and 24 months after index procedure | — |
| Cardiac Death | In hospital and at 30 days,6, 12 and 24 months after index procedure | — |
| Non-Cardiac Death | In hospital and at 30 days,6, 12 and 24 months after index procedure | — |
| Major Bleeding | In hospital and at 30 days,6, 12 and 24 months after index procedure | \[BARC\] definition |
| Net Adverse Clinical and Cerebral Events (NACCE) | In hospital and at 30 days,6, 12 and 24 months after index procedure | — |
Other
| Measure | Time frame | Description |
|---|---|---|
| Cost-Effectiveness Ratio (CER) | At 12 months after index procedure | CER = \[total medical care costs of anti-platelet therapy\] / \[number of participants without net adverse clinical and cerebral events (NACCE)\] |
Countries
China
Contacts
Primary ContactMing Zheng, MD
Outcome results
None listed